Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Wachovia Keeps 'Outperform' on Visx


Wachovia reiterated outperform on Visx (EYE).

Analyst Theodore Huber says marginally better clinical outcomes, and physician support of new technology will drive the commercial success of the commercial LASIK procedure. He expects considerable media attention, and additional local advertising by surgeons to stimulate new demand. Huber says channel checks indicate LASIK interest has been building since the end of the Iraq war, amid a rebound in consumer confidence. He expects custom LASIK to drive profit and cash flow growth well in excess of consensus.

Huber sees 38 cents 2003 earnings per share, and 68 cents for 2004. He has a $20 to $22 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus